- Cell and gene therapy thawing equipment, essential for preserving the viability and efficacy of cryopreserved therapeutic products, is becoming an integral part of advanced therapy manufacturing and clinical workflows due to its ability to offer precise, rapid, and contamination-free thawing solutions
- The escalating demand for thawing equipment is primarily fueled by the global surge in cell and gene therapy development, increased regulatory focus on quality and standardization, and the need for closed, automated systems to ensure consistent product handling
- North America dominated the cell and gene therapy thawing equipment market with the largest revenue share of 42.1% in 2024, supported by its strong biopharma infrastructure, leading role in regenerative medicine innovation, and the presence of major therapy developers and contract manufacturers, particularly in the U.S., which is witnessing rising adoption in both clinical trial sites and commercial production facilities
- Asia-Pacific is expected to be the fastest growing region in the cell and gene therapy thawing equipment market during the forecast period due to expanding biotech investments, growing clinical research activity, and supportive government policies in countries such as China, Japan, and South Korea
- Automated thawing systems segment dominated the market with a market share of 47.2% in 2024, driven by their reliability, scalability, and compliance with good manufacturing practices (GMP), making them the preferred choice for commercial-scale applications
